Digital Look

Welcome to Digital Look++,
you are not logged in

Faron Pharmaceuticals Oy (DI) (FARN)

Pharma and Biotech

35.00p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue ( m)	Pre-tax ( m)	EPS	Dividend
30-Jun-26	Interim	n/a	(8.51)	(6.00)¢	n/a

Year Ending	Revenue ( m)	Pre-tax ( m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-21	n/a	(21.18)	(45.10)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-22	n/a	(28.73)	(55.84)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-23	n/a	(30.94)	(51.54)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-24	n/a	(25.92)	(31.14)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-25	1.31	(27.25)	(25.77)¢	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-26	n/a	(24.22)	(8.82)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-26	n/a	(24.22)	(8.82)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-27	n/a	(30.07)	(10.28)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-27	n/a	(30.07)	(10.28)p	n/a	n/a	n/a	n/a	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	n/a	n/a	n/a	0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.